The Role of IL-17 in the Human Immune System and Its Blockage as a Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis
May 2018 | Volume 17 | Issue 5 | Original Article | 539 | Copyright © 2018
Juan J. Jaller Char MD,a Jose A. Jaller MD,b Juan J. Jaller Raad MD,c Jill S. Waibel MD,b Dhaval G. Bhanusali MD,d and Neha Bhanusali MDa
aUniversity of Central Florida, Orlando, FL bUniversity of Miami Miller School of Medicine, Department of Dermatology & Cutaneous surgery, Miami, FL cCenter of Rheumatology and Orthopedics, Department of Rheumatology in Barranquilla, Colombia dIcahn School of Medicine at Mount Sinai, New York, NY
Interleukin 17 (IL-17) functions as a bridge between the innate and adaptive immunity. In addition to being a crucial defense mechanism against extracellular pathogens, it plays a significant role in inflammation, therefore considered a decisive factor in inflammatory conditions; hence the importance of its understanding for the treatment of autoimmune diseases. Animal models have demonstrated that blockage of the IL-17 receptor (IL-17R) may prevent these pathologies. For instance, there is evidence that IL-17R-deficient mice may be protected against the development of collagen-induced arthritis (CIA) and experimental autoimmune encephalitis (EAE). Furthermore; inflammatory disorders such as rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PSA), and ankylosing spondylitis (AS) have been associated with IL-17, and therapeutically targeting this inflammatory pathway could improve patients’ outcomes. The discovery and subsequent studies of this interleukin have aided in the understanding of the immune system, and its potential therapeutic blockage provokes optimism for the treatment of these distressing conditions. J Drugs Dermatol. 2018;17(5):539-542.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
In 1986, Mosmann and Coffman described two immunologic pathways using murine models. They discovered that the CD4+ T helper (Th) lymphocytes differentiate into two subtypes defined by their function and cytokines.1 Interleukin 12 (IL-12) and Interferon-y (INF-y) stimulate Th1, which is responsible for intracellular pathogen clearance and an inflammatory response. The stimulation of Th2 is induced by IL-4 and controls humoral response and extracellular pathogens. Both pathways (Th1 and Th2) potentiate their own expression and antagonize each other, leading to mutual exclusion.2Later on, the idea that Th1 cells with certain specificity for autoantigens that produce IFN-y introduced the possibility that Th1 cells were autopathogenic and required for the induction of organ-specific autoimmunity. This was based on animal model studies where the expression of INF-y in target tissue correlated with clinical signs of collagen-induced arthritis (CIA) and experimental autoimmune encephalomyelitis (EAE). Also, a polyclonal antibody for IL-12 as a therapy was effective against CIA and EAE. In later animal model studies, it was demonstrated that IL-12 and INF-y deficient mice were not protected against these diseases; instead they were susceptible to more severe forms. These findings indicated that another group of cells different to Th1 were necessary to develop organ-specific autoimmune diseases.2,3In homologous sequence chain studies of IL-6 subfamilies it was discovered that the subunit p19, which forms heterodimers with p40 to form IL-12, was shared by a new cytokine which they called IL-23. Taking this in consideration, an effective treatment would need to target the subunit p40 to affect the development of EAE, since IL-23 and not IL-12 is the determinant for the development of this disease.4 It was then described that IL-23 had a role in Th17 differentiation as well as IL-17 production by leucocytes like macrophages, neutrophils and mastocytes, along with the development of T CD4+ IL-17 producing cells. The discovery of this new pathway IL-23/17 opened the door to a better understanding of the immune system.5
The IL-17 is a homodimeric (or heterodimeric) glycoprotein (35kDa) that works like a bridge between the innate and adaptive immunity.6,7 It plays an important role defending against extracellular pathogens and promoting inflammatory pathologies.8 Six members have been described as part of the family of IL-17: IL-17A, B, C, D, E (also named IL-25), and F. IL-17A has been identified as the most important pro-inflammatory cytokine among the IL-17 family when bound to its receptor. In vivo, IL-17A can be found as a homodimeric glycoprotein (35kDa) made of 2 IL-17A,6 which binds with great affinity to its